SHL pumps $40M into Taiwan delivery industry; FDA grants melphalan orphan status to beleaguered Delcath;

@MichaelGFierce: Vaginal polymer ring delivers long-term HIV-preventing drug. Item | Follow @MichaelGFierce

> Drug delivery devicemaker SHL is investing $40 million in Taiwan, signing a letter of intent with the Taiwan Ministry of Economic Affairs. Story

> The FDA granted Delcath Systems orphan drug designation for the use of melphalan hydrochloride in patients with hepatocellular carcinoma, or primary liver cancer. The company has had trouble with its delivery system for liver cancer in the past. Release

> InSite Vision enrolled patients in a Phase III clinical trial of its BromSite for the reduction of inflammation and pain after cataract surgery. The combination uses the company's InSite delivery tech to deliver a non-steroidal anti-inflammatory. Release

> Austin, TX-based Mystic Pharmaceuticals snagged patent application notices in China and Japan for its dosage-controlling delivery systems. More

> ProStrakan launched its Sancuso transdermal delivery system in Europe with approval from the European Medicines Agency. The company will team with 3M Drug Delivery Systems as a manufacturer. Release

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.